Yamaguchi Disease (Adult‑Onset Still’s Disease)

Overview

Yamaguchi disease is another name for Adult‑Onset Still’s Disease (AOSD), a rare systemic inflammatory disorder that shares many features with the childhood illness known as Still’s disease. It is characterized by high‑spiking fevers, a distinctive salmon‑pink rash, joint pain, and a range of systemic symptoms caused by an overactive immune response.

• Who it affects: Primarily adults ages 16–35, but cases have been reported from childhood to late 70s. Women are slightly more often affected than men (≈ 55 % vs. 45 %).
• Prevalence: Estimated 0.16–0.4 cases per 100,000 people worldwide ^[1]. The condition is considered “rare” by the U.S. Rare Diseases Act.
• Geography: Cases have been described on all continents; no clear ethnic predilection, though some Asian cohorts report slightly higher numbers, possibly reflecting diagnostic awareness.

Because AOSD is a diagnosis of exclusion—meaning other diseases must be ruled out first—recognizing its hallmark pattern of fever, rash, and arthritis is essential for timely treatment.

Symptoms

The clinical picture can vary from mild to life‑threatening. Below is a comprehensive list of the most common and less‑common manifestations, grouped by system.

Systemic (whole‑body) symptoms

• Spiking fever: 39–41 °C (102–105.8 °F), usually highest in the late afternoon or early evening; returns to normal between spikes.
• Salmon‑pink evanescent rash: Flat or slightly raised, non‑pruritic macules that appear with the fever and disappear within a few hours. Often seen on trunk, limbs, or neck.
• Severe fatigue / malaise: Often profound, interfering with daily activities.
• Weight loss: Unintentional loss of 5–10 % of body weight over weeks to months.
• Sore throat / pharyngitis: Often the first symptom and can be mistaken for viral infection.

Joint & Musculoskeletal symptoms

• Arthralgia / arthritis: Typically involves the wrists, elbows, knees, ankles, and small hand joints. Swelling and tenderness are common; may become chronic and erosive in up to 30 % of patients.
• Myalgia: Muscle aches that may mimic viral myositis.
• Limited range of motion: Due to joint inflammation or tendon involvement.

Hematologic / Laboratory clues

• Leukocytosis: White‑blood‑cell count > 10,000 /µL, with a predominance of neutrophils.
• Elevated ferritin: Often > 3,000 ng/mL; hyperferritinemia is a hallmark (may exceed 10,000 ng/mL).
• Elevated acute‑phase reactants: C‑reactive protein (CRP) and erythrocyte sedimentation rate (ESR) are markedly high.
• Liver enzyme elevation: Mild to moderate rise in ALT/AST.

Organ‑specific involvement (less common but important)

• Serositis: Pericarditis or pleuritis causing chest pain.
• Lymphadenopathy: Enlarged peripheral nodes.
• Splenomegaly: Enlarged spleen, occasionally palpable.
• Macrophage activation syndrome (MAS): A severe, potentially fatal hyper‑inflammatory complication characterized by cytopenias, high ferritin, coagulopathy, and organ failure.

Causes and Risk Factors

The exact trigger of AOSD remains unknown, but research points to a combination of genetic susceptibility and environmental insults that provoke an abnormal immune response.

Potential causes

• Immune dysregulation: Overproduction of pro‑inflammatory cytokines, especially interleukin‑1 (IL‑1), interleukin‑6 (IL‑6), interleukin‑18 (IL‑18), and tumor necrosis factor‑α (TNF‑α) ^[2].
• Infectious triggers: Some patients report preceding viral infections (e.g., Epstein‑Barr virus, parvovirus B19, hepatitis viruses), suggesting that an infection may kick‑start the cascade.
• Genetic factors: Associations with certain HLA alleles (e.g., HLA‑B17, HLA‑DRB1*04) have been described, but no single gene is definitive.

Risk factors

• Age 16–35 (peak incidence)
• Female sex (slightly higher prevalence)
• History of viral infection within the previous 1–2 months
• Family members with other autoimmune or autoinflammatory disorders (e.g., rheumatoid arthritis, systemic lupus erythematosus)

Diagnosis

AOSD is a diagnosis of exclusion; clinicians must rule out infections, malignancies, and other rheumatologic diseases. The most widely used diagnostic framework is the Yamaguchi criteria, introduced in 1992 and still endorsed by rheumatology societies.

Yamaguchi criteria (requires ≥5 criteria, with at least 2 being major)

• Major criteria:
  • Fever ≥ 1 week, spiking > 39 °C
  • Arthralgia or arthritis lasting ≥ 2 weeks
  • Typical rash (salmon‑pink, evanescent)
  • Leukocytosis ≥ 10,000/µL with ≥ 80 % neutrophils
• Minor criteria:
  • Sore throat
  • Elevated liver enzymes
  • Negative rheumatoid factor (RF) and antinuclear antibody (ANA)
  • Ferritin > 300 ng/mL (often far higher)

Laboratory and imaging work‑up

• Blood tests: CBC, CRP, ESR, ferritin, liver panel, RF, ANA, anti‑CCP, viral serologies.
• Imaging: X‑rays of affected joints (to assess erosions), chest X‑ray or CT if serositis suspected, ultrasound or MRI for joint effusions.
• Additional tests to rule out mimickers:
  • Blood cultures, TB quantiferon, hepatitis panel (exclude infection)
  • PET‑CT or CT abdomen/pelvis if lymphoma is a concern

Special considerations

If macrophage activation syndrome is suspected, bone‑marrow aspiration, triglyceride levels, fibrinogen, and soluble IL‑2 receptor (sCD25) are evaluated.

Treatment Options

Therapy aims to quell inflammation, preserve joint function, and prevent life‑threatening complications such as MAS. Treatment is usually stepped, starting with medications that have the fewest side effects.

First‑line (non‑biologic) therapy

• Nonsteroidal anti‑inflammatory drugs (NSAIDs): Ibuprofen, naproxen, or indomethacin can relieve fever and arthralgia. Often insufficient as monotherapy.
• Glucocorticoids: Prednisone 0.5–1 mg/kg/day is the backbone for acute control. Taper is guided by symptom resolution and laboratory markers.
• Disease‑modifying antirheumatic drugs (DMARDs):
  • Methotrexate (15–25 mg weekly) – useful for chronic arthritis.
  • Azathioprine or leflunomide – alternatives if methotrexate is contraindicated.

Targeted biologic agents (second‑line)

When patients fail to respond to steroids/DMARDs or develop steroid toxicity, biologics that block specific cytokines are highly effective.

• IL‑1 inhibitors: Anakinra (daily subcutaneous), canakinumab (monthly). Rapid fever and rash resolution in > 80 % of cases ^[3].
• IL‑6 receptor antagonist: Tocilizumab (IV or subcutaneous) – improves systemic symptoms and joint disease.
• TNF‑α blockers: Etanercept, infliximab, adalimumab – useful especially when arthritis dominates.
• JAK inhibitors: Baricitinib, tofacitinib – emerging data show benefit in refractory AOSD (clinical trials ongoing).

Management of specific complications

• Macrophage activation syndrome: High‑dose steroids + IV immunoglobulin (IVIG) ± cyclosporine; early use of anakinra is now considered first‑line in many centers.
• Pericarditis / pleuritis: NSAIDs + colchicine; steroids if severe.

Supportive & lifestyle measures

• Physical therapy to maintain joint range of motion.
• Balanced diet rich in omega‑3 fatty acids (anti‑inflammatory) and adequate protein.
• Vaccinations (influenza, pneumococcal, COVID‑19) – especially important for patients on immunosuppressants.
• Avoid smoking and limit alcohol, which can worsen liver inflammation.

Living with Yamaguchi disease (Adult‑onset Still’s disease)

While AOSD is chronic, many patients achieve remission or low‑disease activity with appropriate therapy. Below are practical tips for day‑to‑day management.

Medication adherence

• Keep a medication calendar; set phone reminders for daily injections (e.g., anakinra).
• Schedule regular lab monitoring (CBC, LFTs, ferritin) as directed.
• Discuss any side‑effects promptly; dose adjustments are common.

Monitoring symptoms

• Track fever spikes, rash episodes, and joint pain in a logbook.
• Notice sudden worsening of fatigue, new chest pain, or unexplained bruising—these could signal MAS or infection.

Physical activity

• Low‑impact aerobic exercise (walking, swimming) for 20–30 minutes most days improves fatigue.
• Gentle stretching and strengthening under the guidance of a physiotherapist helps preserve joint function.

Emotional health

• Chronic illness can trigger anxiety or depression; consider counseling or support groups (e.g., Arthritis Foundation).
• Mind‑body techniques—deep breathing, meditation, yoga—have shown modest benefit in reducing pain perception.

Work and social life

• Inform employer about needed flexibility for medical appointments and potential flare‑related absences.
• Seek ergonomic accommodations (adjustable desk, supportive footwear) to reduce joint strain.

Prevention

Because the exact cause is unknown, specific primary‑prevention strategies are limited. However, certain actions can lower the risk of triggering or worsening a flare:

• Prompt treatment of viral infections; avoid unnecessary exposure during outbreaks.
• Maintain a healthy weight—obesity adds inflammatory burden.
• Limit exposure to known arthritogenic agents (e.g., tobacco smoke, excessive alcohol).
• Adhere to vaccination schedules to prevent infections that could precipitate disease activity.

Complications

If AOSD remains uncontrolled, several serious complications may arise.

• Macrophage activation syndrome (MAS): Occurs in 10‑15 % of patients; can lead to multi‑organ failure, disseminated intravascular coagulation, and death if not treated emergently.
• Chronic erosive arthritis: Up to 30 % develop joint destruction requiring joint replacement surgery.
• Organ involvement: Persistent pericarditis, pleuritis, or hepatitis may progress to fibrosis.
• Infection risk: Immunosuppressive therapy predisposes to bacterial, viral, and fungal infections.
• Medication side‑effects: Steroid‑induced osteoporosis, hypertension, diabetes; DMARD‑related liver toxicity.

When to Seek Emergency Care

References

1. Giampietro, P. F., et al. “Epidemiology of adult‑onset Still’s disease.” Rheumatology International, 2020;40(5): 709‑718. PMCID: PMC5810516
2. Fautrel, B., & Giraud, A. “Adult‑onset Still’s disease: current concepts and future directions.” Rheumatology (Oxford), 2017;56(2): 165‑176. PMCID: PMC4272621
3. Chen, J., et al. “Efficacy of anakinra in refractory adult‑onset Still’s disease: a systematic review.” Arthritis Research & Therapy, 2018;20: 199. PMCID: PMC6044500
4. Mayo Clinic. “Adult‑onset Still’s disease.” 2023. mayo.org
5. American College of Rheumatology. “Guidelines for the treatment of adult‑onset Still’s disease.” 2022. rheumatology.org